| Cash Flow | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
| Net loss (including amounts attributable to redeemable non-controlling interests) | -25,492 | -31,582 | -35,800 | -27,763 |
| Stock-based compensation | 35,804 | 37,712 | 37,828 | 37,555 |
| Amortization of deferred contract costs | 12,280 | 11,335 | 10,481 | 10,030 |
| Depreciation and amortization | 6,284 | 5,969 | 5,987 | 4,766 |
| Provision for credit losses | -78 | 18 | 48 | 368 |
| Value of common stock donated to charity | 500 | 691 | 672 | 751 |
| Accretion of discount on marketable securities | -78 | -129 | -168 | -255 |
| Non-cash foreign exchange (gain) loss | -288 | -116 | 398 | 18 |
| Fair value adjustments to contingent consideration | NaN | 0 | 0 | 0 |
| Fixed asset write offs | NaN | 42 | 38 | NaN |
| Deferred tax asset | -263 | NaN | NaN | NaN |
| Other | 6 | 144 | 28 | -37 |
| Accounts receivable | -3,848 | 32,214 | 2,050 | -2,441 |
| Prepaid expenses and other current assets | 6,961 | 4,394 | -2,927 | -1,889 |
| Deferred contract costs | 15,342 | 26,034 | 14,401 | 12,944 |
| Rou assets and liabilities | -273 | 499 | 320 | -96 |
| Other assets | 805 | -6,987 | 416 | 8,048 |
| Accounts payable | 3,833 | -1,956 | 2,514 | -181 |
| Accrued expenses and other current liabilities | -20,889 | 20,258 | 4,715 | 8,421 |
| Deferred revenue | 38,211 | 33,174 | 9,470 | -10,054 |
| Other long-term liabilities | -3,293 | 25 | -132 | -121 |
| Net cash provided by operating activities | 28,126 | 19,375 | 20,967 | 6,952 |
| Cash paid for acquisition, net of cash acquired | NaN | -35 | 689 | 181,200 |
| Purchases of property and equipment | 108 | 4,820 | 1,942 | 2,609 |
| Capitalized internal-use software costs | 1,227 | 665 | 1,246 | 810 |
| Purchases of marketable securities | 26,662 | 39,722 | 36,804 | 22,751 |
| Maturities of marketable securities | 35,870 | 37,709 | 34,959 | 39,325 |
| Return of principal on marketable securities | 34,923 | 0 | -9 | 7,495 |
| Net cash provided by investing activities | 42,796 | -7,463 | -5,731 | -160,550 |
| Proceeds from exercise of common stock options | 310 | 11,578 | 1,082 | 2,596 |
| Proceeds from stock associated with employee stock purchase plan | NaN | 2,217 | 0 | 4,882 |
| Payments of deferred purchase consideration | NaN | 0 | 0 | 0 |
| Repurchase of common stock | 50,000 | NaN | NaN | NaN |
| Net cash provided by/(used in) financing activities | -49,690 | 13,795 | 1,082 | 7,478 |
| Effect of foreign currency exchange rate changes on cash, cash equivalents, and restricted cash | -285 | 820 | -207 | -209 |
| Net change in cash, cash equivalents, and restricted cash | 20,947 | 26,527 | 16,111 | -146,329 |
| Cash, cash equivalents, and restricted cash, beginning of period | 128,338 | 101,811 | 85,700 | 232,029 |
| Cash, cash equivalents, and restricted cash, end of period | 149,285 | 128,338 | 101,811 | 85,700 |
Braze, Inc. (BRZE)
Braze, Inc. (BRZE)